Chinese Journal of Clinical Pharmacology and Therapeutics ›› 2026, Vol. 31 ›› Issue (6): 827-835.doi: 10.12092/j.issn.1009-2501.2026.06.012
Ailin LU1(
), Mengrui YUAN1, Yongqing WU1, Hongyi LIU2(
)
Received:2025-01-09
Online:2026-06-26
Published:2026-07-06
CLC Number:
Ailin LU, Mengrui YUAN, Yongqing WU, Hongyi LIU. Progress of Chinese medicine intervention in HMGB1 pathway to improve type 2 diabetes mellitus and its complications[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2026, 31(6): 827-835.
| 中药活 性成分 | 来源 | 疾病 类别 | 实验 对象 | 作用机制与靶点 | 参考 文献 |
| 茯苓酸 | 茯苓 | IR | SD大鼠 | 抑制HMGB1/RAGE信号通路,HMGB1、RAGE、p-NF-κBp65↓, FINS、HOMA-IR、TNF-α、IL-1β↓ | [ |
| 红景天苷 | 红景天 | IR | db/db小鼠 | 抑制HMGB1/RAGE/NF-κB信号通路 | [ |
| 栀子苷 | 栀子 | IR | GDM大鼠 | 抑制HMGB1/RAGE信号,HMGB1、RAGE↓,FPG、FINS、IRITC、 TG、LDL-C↓,HDL-C、CTRP3、GLUT4↑ | [ |
| 欧前胡素 | 蛇床子 | DR | HRMECs | 抑制HMGB1/RAGE/NF-κB信号通路,IL-6、TNF-α、IL-1β、MDA↓ | [ |
| 芸香苷 | 槐花 | DR | SD大鼠 | 抑制HMGB1/RAGE信号通路,HMGB1、RAGE mRNA、miR-155↓ | [ |
| 甘草甜素 | 甘草 | DR | C57BL/6小鼠 | HMGB1、RAGE↓,IL-6、IL-1β↓ | [ |
| DCM | H9c2细胞 | 抑制HMGB1/RAGE信号通路,HMGB1、RAGE mRNA、IL-1β、TNF-α、ROS↓,细胞凋亡率、Bax、LC3、Beclin-1↓ | [ | ||
| DKD | SD大鼠、RSC96细胞 | HMGBI、RAGE↓,抑制NF-κB易位,ERK、p38MAPK磷酸化↓ | [ | ||
| DPN | SD大鼠、RSC96细胞 | 阻断HMGB1及抑制RAGE/p38MAPK/NF-κBp65信号通路,NGF、 neuritin-1、caspase-3↓,促进坐骨神经恢复 | [ | ||
| 青蒿素 | 青蒿 | DCM | SD大鼠 | 调节AGE-RAGE/HMGB1信号通路,IL-1β↓ | [ |
| 槲皮素 | 银杏叶 | DKD | SD大鼠 | 抑制HMGB1/RAGE/NF-κB信号通路,IL-1β、IL-6、TNF-α↓,Bax、 Caspase-3↓,Bcl-2↑ | [ |
| 川芎嗪 | 川芎 | DKD | SD大鼠 | 抑制HMGB1/RAGEs信号通路,RAGEs、Cr、BUN↓ | [ |
| 穿心莲内酯 | 穿心莲 | DPN | SD大鼠 | 抑制HMGB1/RAGE信号通路,HMGB1、RAGE、NF-κBp65、MDA、 氧化应激↓,SOD↑ | [ |
| 连翘苷 | 连翘 | DPN | SD大鼠 | 抑制HMGB1/RAGE信号通路,HMGB1、RAGE mRNA、IL-6、TNF-a、 ROS、MDA、FPG、HbAlc↓,MBP、SOD↑ | [ |
Table 1 Summary of TCM active ingredients based on HMGB1/RAGE signaling pathway for the treatment of T2DM and its complications
| 中药活 性成分 | 来源 | 疾病 类别 | 实验 对象 | 作用机制与靶点 | 参考 文献 |
| 茯苓酸 | 茯苓 | IR | SD大鼠 | 抑制HMGB1/RAGE信号通路,HMGB1、RAGE、p-NF-κBp65↓, FINS、HOMA-IR、TNF-α、IL-1β↓ | [ |
| 红景天苷 | 红景天 | IR | db/db小鼠 | 抑制HMGB1/RAGE/NF-κB信号通路 | [ |
| 栀子苷 | 栀子 | IR | GDM大鼠 | 抑制HMGB1/RAGE信号,HMGB1、RAGE↓,FPG、FINS、IRITC、 TG、LDL-C↓,HDL-C、CTRP3、GLUT4↑ | [ |
| 欧前胡素 | 蛇床子 | DR | HRMECs | 抑制HMGB1/RAGE/NF-κB信号通路,IL-6、TNF-α、IL-1β、MDA↓ | [ |
| 芸香苷 | 槐花 | DR | SD大鼠 | 抑制HMGB1/RAGE信号通路,HMGB1、RAGE mRNA、miR-155↓ | [ |
| 甘草甜素 | 甘草 | DR | C57BL/6小鼠 | HMGB1、RAGE↓,IL-6、IL-1β↓ | [ |
| DCM | H9c2细胞 | 抑制HMGB1/RAGE信号通路,HMGB1、RAGE mRNA、IL-1β、TNF-α、ROS↓,细胞凋亡率、Bax、LC3、Beclin-1↓ | [ | ||
| DKD | SD大鼠、RSC96细胞 | HMGBI、RAGE↓,抑制NF-κB易位,ERK、p38MAPK磷酸化↓ | [ | ||
| DPN | SD大鼠、RSC96细胞 | 阻断HMGB1及抑制RAGE/p38MAPK/NF-κBp65信号通路,NGF、 neuritin-1、caspase-3↓,促进坐骨神经恢复 | [ | ||
| 青蒿素 | 青蒿 | DCM | SD大鼠 | 调节AGE-RAGE/HMGB1信号通路,IL-1β↓ | [ |
| 槲皮素 | 银杏叶 | DKD | SD大鼠 | 抑制HMGB1/RAGE/NF-κB信号通路,IL-1β、IL-6、TNF-α↓,Bax、 Caspase-3↓,Bcl-2↑ | [ |
| 川芎嗪 | 川芎 | DKD | SD大鼠 | 抑制HMGB1/RAGEs信号通路,RAGEs、Cr、BUN↓ | [ |
| 穿心莲内酯 | 穿心莲 | DPN | SD大鼠 | 抑制HMGB1/RAGE信号通路,HMGB1、RAGE、NF-κBp65、MDA、 氧化应激↓,SOD↑ | [ |
| 连翘苷 | 连翘 | DPN | SD大鼠 | 抑制HMGB1/RAGE信号通路,HMGB1、RAGE mRNA、IL-6、TNF-a、 ROS、MDA、FPG、HbAlc↓,MBP、SOD↑ | [ |
| 中药活 性成分 | 来源 | 疾病类别 | 实验对象 | 作用机制与靶点 | 参考文献 |
| 红景天苷 | 红景天 | IR | db/db小鼠 | 抑制HMGB1/TLR4/NLRP3信号通路 | [ |
| 大黄素 | 大黄 | IR | PCOS小鼠 | 抑制HMGB1/TLR4/NF-κB通路,GLUT4、IRS2、INSR↑ | [ |
| 西红花苷 | 红花 | DR | SD大鼠 | 抑制HMGB1/TLR4/MyD88/NF-κB通路和NF-κB核转位, TNF-α、IL-1β、IL-8、sICAM-1↓ | [ |
| 银杏二萜内酯 | 银杏叶 | DR | SD大鼠 | 抑制HMGB1/TLR4/NF-κB信号通路,IL-1β、TNF-α、IL-6、IL-8↓ | [ |
| 芍药苷 | 芍药 | DR | CD-1小鼠 | 抑制HMGB1/TLR4/NF-κB和HSP70/TLR4/NF-κB信号通路, SOCS3↑,MMP-9↓ | [ |
| 甘草甜素 | 甘草 | DR | C57BL/6小鼠 | HMGB1、TLR4↓,IL-6、IL-1β↓ | [ |
| DKD | SD大鼠、RSC96细胞 | HMGBI、TLR4↓,抑制NF-κB易位,ERK、p38MAPK磷酸化↓ | [ | ||
| 桂皮醛 | 桂皮 | DCM | SD大鼠 | 抑制HMGB1/TLR4/NF-κB信号通路,FPG、LVEDD、LVESD、CVF↓,IL-6、IL-1β、TNF-α↓ | [ |
| 牛磺酸 | 牛胆汁 | DKD | C57BL/6小鼠 | 抑制HMGB1/TLR4信号通路,IL-6、TNF-α、IL-1β↓、NF-κBp65、MyD88、CD68、MCP-1↓ | [ |
| 鞣花酸 | 石榴皮 | DKD | SD大鼠 | 抑制HMGB1/TLR4/NF-κB信号通路,IRAK4、TRAF6、IKK-β、 NF-κBp65↓ | [ |
| 五味子乙素 | 五味子 | DKD | SD大鼠 | 抑制HMGB1/TLR4信号通路,HMGB1、TLR4、IL-1β、TNF-α、 IL-6↓,Scr、Cys-c、ALT、↓,Ucr、Ccr↑ | [ |
| 柴胡多糖 | 柴胡 | DKD | SD大鼠 | 抑制HMGB1/TLR4信号,TNF-α、IL-6↓,ColIV、FN、α-SMA↓ | [ |
| 红芪多糖 | 红芪 | DPN | SD大鼠 | 调控HMGB1/TLR4信号通路,NF-κB、IL-1、mRNA↓ | [ |
Table 2 Summary of herbal active ingredients based on HMGB1/TLRs signaling pathway for the treatment of T2DM and its complications
| 中药活 性成分 | 来源 | 疾病类别 | 实验对象 | 作用机制与靶点 | 参考文献 |
| 红景天苷 | 红景天 | IR | db/db小鼠 | 抑制HMGB1/TLR4/NLRP3信号通路 | [ |
| 大黄素 | 大黄 | IR | PCOS小鼠 | 抑制HMGB1/TLR4/NF-κB通路,GLUT4、IRS2、INSR↑ | [ |
| 西红花苷 | 红花 | DR | SD大鼠 | 抑制HMGB1/TLR4/MyD88/NF-κB通路和NF-κB核转位, TNF-α、IL-1β、IL-8、sICAM-1↓ | [ |
| 银杏二萜内酯 | 银杏叶 | DR | SD大鼠 | 抑制HMGB1/TLR4/NF-κB信号通路,IL-1β、TNF-α、IL-6、IL-8↓ | [ |
| 芍药苷 | 芍药 | DR | CD-1小鼠 | 抑制HMGB1/TLR4/NF-κB和HSP70/TLR4/NF-κB信号通路, SOCS3↑,MMP-9↓ | [ |
| 甘草甜素 | 甘草 | DR | C57BL/6小鼠 | HMGB1、TLR4↓,IL-6、IL-1β↓ | [ |
| DKD | SD大鼠、RSC96细胞 | HMGBI、TLR4↓,抑制NF-κB易位,ERK、p38MAPK磷酸化↓ | [ | ||
| 桂皮醛 | 桂皮 | DCM | SD大鼠 | 抑制HMGB1/TLR4/NF-κB信号通路,FPG、LVEDD、LVESD、CVF↓,IL-6、IL-1β、TNF-α↓ | [ |
| 牛磺酸 | 牛胆汁 | DKD | C57BL/6小鼠 | 抑制HMGB1/TLR4信号通路,IL-6、TNF-α、IL-1β↓、NF-κBp65、MyD88、CD68、MCP-1↓ | [ |
| 鞣花酸 | 石榴皮 | DKD | SD大鼠 | 抑制HMGB1/TLR4/NF-κB信号通路,IRAK4、TRAF6、IKK-β、 NF-κBp65↓ | [ |
| 五味子乙素 | 五味子 | DKD | SD大鼠 | 抑制HMGB1/TLR4信号通路,HMGB1、TLR4、IL-1β、TNF-α、 IL-6↓,Scr、Cys-c、ALT、↓,Ucr、Ccr↑ | [ |
| 柴胡多糖 | 柴胡 | DKD | SD大鼠 | 抑制HMGB1/TLR4信号,TNF-α、IL-6↓,ColIV、FN、α-SMA↓ | [ |
| 红芪多糖 | 红芪 | DPN | SD大鼠 | 调控HMGB1/TLR4信号通路,NF-κB、IL-1、mRNA↓ | [ |
| 中药活 性成分 | 来源 | 疾病 类别 | 实验对象 | 作用机制与靶点 | 参考 文献 |
| 香青兰总黄酮 | 薄荷 | IR | SD大鼠 | HMGB1、IAA、TNF-α、IL-1β、IL-6、IL-18、CRP、LP↓,INS、ADPN↑ | [ |
| 姜黄素 | 姜黄 | IR | db/db小鼠、 H9c2细胞 | 抑制HMGB1/NLRP3/NF-κB信号通路,IL-1β、TNF-α、IL-6、 TGF-β↓ | [ |
| 荞麦黄酮 | 荞麦 | DR | HRMECs | HMGB1、IL-6、TNF-α↓,IL-10↑ | [ |
| 芒果苷 | 芒果叶 | DR | SD大鼠 | 抑制Nrf-2/HO-1/HMGB1/NF-κB信号通路,IL-1β、IL-6、TNF-α、 MDA↓ | [ |
| 葛花总黄酮 | 葛根 | DR | C57BL/6小鼠 | 抑制HMGB1信号通路,VEGF、NF-κB、TNF-α↓ | [ |
| 白藜芦醇 | 虎杖 | DR | HRMECs | 抑制SIRT-1/HMGB1信号通路,VEGF↓ | [ |
| 二氢杨梅素 | 地榆 | DCM | SD大鼠 | HMGB1、NF-κBp65磷酸化↓,EF、FS、SV↑,LVIDd、LVIDs、 心脏肥厚指数↓ | [ |
| 姜黄素 | 姜黄 | DCM | db/db小鼠、 H9c2细胞 | 抑制HMGB1/NLRP3/NF-κB信号通路,IL-1β、TNF-α、IL-6、TGF-β↓ | [ |
| 黄芪甲苷 | 黄芪 | DKD | DN细胞 | 抑制HMGB1/AGEs/NF-κB信号通路 | [ |
| 毛蕊花糖苷 | 夏枯草 | DKD | C57BL/6小鼠 | HMGB1、NF-κB↓,24hUP、BUN、Cr↓ | [ |
Table 3 Summary of active ingredients of traditional Chinese medicine intervening in HMGB1 other related pathway pathways for the treatment of T2DM and its complications
| 中药活 性成分 | 来源 | 疾病 类别 | 实验对象 | 作用机制与靶点 | 参考 文献 |
| 香青兰总黄酮 | 薄荷 | IR | SD大鼠 | HMGB1、IAA、TNF-α、IL-1β、IL-6、IL-18、CRP、LP↓,INS、ADPN↑ | [ |
| 姜黄素 | 姜黄 | IR | db/db小鼠、 H9c2细胞 | 抑制HMGB1/NLRP3/NF-κB信号通路,IL-1β、TNF-α、IL-6、 TGF-β↓ | [ |
| 荞麦黄酮 | 荞麦 | DR | HRMECs | HMGB1、IL-6、TNF-α↓,IL-10↑ | [ |
| 芒果苷 | 芒果叶 | DR | SD大鼠 | 抑制Nrf-2/HO-1/HMGB1/NF-κB信号通路,IL-1β、IL-6、TNF-α、 MDA↓ | [ |
| 葛花总黄酮 | 葛根 | DR | C57BL/6小鼠 | 抑制HMGB1信号通路,VEGF、NF-κB、TNF-α↓ | [ |
| 白藜芦醇 | 虎杖 | DR | HRMECs | 抑制SIRT-1/HMGB1信号通路,VEGF↓ | [ |
| 二氢杨梅素 | 地榆 | DCM | SD大鼠 | HMGB1、NF-κBp65磷酸化↓,EF、FS、SV↑,LVIDd、LVIDs、 心脏肥厚指数↓ | [ |
| 姜黄素 | 姜黄 | DCM | db/db小鼠、 H9c2细胞 | 抑制HMGB1/NLRP3/NF-κB信号通路,IL-1β、TNF-α、IL-6、TGF-β↓ | [ |
| 黄芪甲苷 | 黄芪 | DKD | DN细胞 | 抑制HMGB1/AGEs/NF-κB信号通路 | [ |
| 毛蕊花糖苷 | 夏枯草 | DKD | C57BL/6小鼠 | HMGB1、NF-κB↓,24hUP、BUN、Cr↓ | [ |
| 1 |
Chen R, Zou J, Zhong X, et al. HMGB1 in the interplay between autophagy and apoptosis in cancer[J]. Cancer Lett, 2024, 581, 216494.
doi: 10.1016/j.canlet.2023.216494 |
| 2 |
Meng Q, Ma J, Suo L, et al. Galantamine improves glycemic control and diabetic nephropathy in Leprdb/db mice[J]. Sci Rep, 2023, 13 (1): 15544.
doi: 10.1038/s41598-023-42665-2 |
| 3 |
Behl T, Sharma E, Sehgal A, et al. Expatiating the molecular approaches of HMGB1 in diabetes mellitus: highlighting signalling pathways via RAGE and TLRs[J]. Mol Biol Rep, 2021, 48 (3): 1869- 1881.
doi: 10.1007/s11033-020-06130-x |
| 4 | Wang Y, Zhong J, Zhang X, et al. The role of HMGB1 in the pathogenesis of type 2 diabetes[J]. J Diabetes Res, 2016, 2016 (1): 2543268. |
| 5 | 唐虹, 李林霞, 华宇, 等. 茯苓酸改善多囊卵巢综合征大鼠胰岛素抵抗的作用及机制研究[J]. 中国药房, 2024, 35 (1): 57- 62. |
| 6 |
Yang L, Zhou L, Wang X, et al. Inhibition of HMGB1 involved in the protective of salidroside on liver injury in diabetes mice[J]. Int Immunopharmacol, 2020, 89 (1): 106987.
doi: 10.1016/j.intimp.2020.106987 |
| 7 |
亢丽娟, 董海平, 宋艳艳. 栀子苷调节HMGB1-RAGE信号通路对妊娠期糖尿病大鼠胰岛素抵抗的影响[J]. 解剖学研究, 2024, 46 (2): 176- 182+190.
doi: 10.20021/j.cnki.1671-0770.2024.02.14 |
| 8 |
Jiang Y, Steinle JJ. HMGB1 inhibits insulin signalling through TLR4 and RAGE in human retinal endothelial cells[J]. Growth Factors, 2018, 36 (3/4): 164- 171.
doi: 10.1080/08977194.2018.1539393 |
| 9 |
马静, 王齐, 陈彩玲, 等. 欧前胡素调节HMGB1-RAGE-NF-κB信号通路对高糖诱导的视网膜内皮细胞损伤的影响[J]. 中国细胞生物学学报, 2024, 46 (8): 1506- 1514.
doi: 10.11844/cjcb.2024.08.0004 |
| 10 |
王雅清, 王勇, 刘永胜. 芦丁调控miR-155和HMGB1/RAGE通路对糖尿病视网膜病变大鼠炎性反应的影响[J]. 陕西医学杂志, 2024, 53 (2): 184- 188.
doi: 10.3969/j.issn.1000-7377.2024.02.008 |
| 11 |
Hou Y, Xin M, Li Q, et al. Glycyrrhizin micelle as a genistein nanocarrier: synergistically promoting corneal epithelial wound healing through blockage of the HMGB1 signaling pathway in diabetic mice[J]. Exp Eye Res, 2021, 204, 108454.
doi: 10.1016/j.exer.2021.108454 |
| 12 | Wu B, Lin J, Luo J, et al. Dihydromyricetin protects against diabetic cardiomyopathy in streptozotocin‐induced diabetic mice[J]. Biomed Res Int, 2017, 2017, 3764370. |
| 13 |
潘娟, 王琪, 田艳妮. 甘草甜素调节HMGB1/RAGE信号通路对高糖诱导的心肌细胞凋亡和自噬的影响[J]. 中西医结合心脑血管病杂志, 2024, 22 (11): 1961- 1966.
doi: 10.12102/j.issn.1672-1349.2024.11.007 |
| 14 |
Farrag EAE, Hammad MO, Safwat SM, et al. Artemisinin attenuates type 2 diabetic cardiomyopathy in rats through modulation of AGE-RAGE/HMGB-1 signaling pathway[J]. Sci Rep, 2023, 13 (1): 11043.
doi: 10.1038/s41598-023-37678-w |
| 15 |
Cheng M, Liu H, Zhang D, et al. HMGB1 enhances the AGE-induced expression of CTGF and TGF-β via RAGE-dependent signaling in renal tubular epithelial cells[J]. Am J Nephrol, 2015, 41 (3): 257- 266.
doi: 10.1159/000381464 |
| 16 |
Zhang H, Zhang R, Chen J, et al. High mobility group box1 inhibitor glycyrrhizic acid attenuates kidney injury in streptozotocin-induced diabetic rats[J]. Kidney Blood Press Res, 2018, 42 (5): 894- 904.
doi: 10.1159/000485045 |
| 17 |
姜一凡, 李小荣, 耿嘉逸, 等. 槲皮素通过抑制HMGB1/RAGE/NF-κB信号通路减轻糖尿病引起的大鼠肾脏损伤[J]. 南方医科大学学报, 2024, 44 (9): 1769- 1775.
doi: 10.12122/j.issn.1673-4254.2024.09.17 |
| 18 | 傅永锦, 夏雪怡, 张小牧, 等. 川芎嗪对糖尿病肾病大鼠下调HMGB1表达及降低RAGEs作用[J]. 中国临床药理学与治疗学, 2017, 22 (8): 846- 851. |
| 19 |
Abdelkader NF, Ibrahim SM, Moustafa PE, et al. Inosine mitigated diabetic peripheral neuropathy via modulating GLO1/AGEs/RAGE/NF-κB/Nrf2 and TGF-β/PKC/TRPV1 signaling pathways[J]. Biomed Pharmacother, 2022, 145, 112395.
doi: 10.1016/j.biopha.2021.112395 |
| 20 |
Aghamiri SH, Komlakh K, Ghaffari M. Toll-like receptors (TLRs) and their potential therapeutic applications in diabetic neuropathy[J]. Int Immunopharmacol, 2022, 102, 108398.
doi: 10.1016/j.intimp.2021.108398 |
| 21 |
孙跃先, 王九妹, 崔新刚, 等. 穿心莲内酯调节HMGB1/RAGE信号通路对糖尿病周围神经病变大鼠坐骨神经功能损伤的影响[J]. 中国药房, 2024, 35 (5): 572- 577.
doi: 10.6039/j.issn.1001-0408.2024.05.11 |
| 22 |
Shi M, Zhang X, Zhang R, et al. Glycyrrhizic acid promotes sciatic nerves recovery in type 1 diabetic rats and protects Schwann cells from high glucose-induced cytotoxicity[J]. J Biomed Res, 2022, 36 (3): 181.
doi: 10.7555/JBR.36.20210198 |
| 23 |
郑领涛, 申妍姣, 宋丽明. 连翘苷抑制HMGB1/RAGE信号通路减轻大鼠糖尿病周围神经病变坐骨神经损伤[J]. 免疫学杂志, 2024, 40 (1): 46- 52.
doi: 10.13431/j.cnki.immunol.j.20240007 |
| 24 |
Škrha Jr J, Kalousova M, Švarcová J, et al. Relationship of soluble RAGE and RAGE ligands HMGB1 and EN-RAGE to endothelial dysfunction in type 1 and type 2 diabetes mellitus[J]. Exp Clin Endocrinol Diabetes, 2012, 120 (5): 277- 281.
doi: 10.1055/s-0031-1283161 |
| 25 |
Otoo A, Czika A, Lamptey J, et al. Emodin improves glucose metabolism and ovarian function in PCOS mice via the HMGB1/TLR4/NF-κB molecular pathway[J]. Reproduction, 2023, 166 (5): 323- 336.
doi: 10.1530/REP-22-0449 |
| 26 |
Zhao H, Zhang J, Yu J. HMGB-1 as a potential target for the treatment of diabetic retinopathy[J]. Med Sci Monit Int Med J Exp Clin Res, 2015, 21, 3062.
doi: 10.12659/msm.894453 |
| 27 |
Jiang S, Chen X. HMGB1 siRNA can reduce damage to retinal cells induced by high glucose in vitro and in vivo[J]. Drug Des Devel Ther, 2017, 11, 783- 795.
doi: 10.2147/DDDT.S129913 |
| 28 |
孟宏, 王桂青, 杜竹君. 西红花苷通过调控TLR4/MyD88/NF-κB通路改善糖尿病大鼠视网膜病变机制研究[J]. 陕西医学杂志, 2023, 52 (5): 531- 535+540.
doi: 10.3969/j.issn.1000-7377.2023.05.008 |
| 29 |
高明, 徐丽丽, 王利存, 等. 基于TLR4/NF-κB信号通路探讨银杏二萜内酯对糖尿病大鼠视网膜病变的影响[J]. 天津中医药, 2023, 40 (5): 654- 661.
doi: 10.11656/j.issn.1672-1519.2023.05.20 |
| 30 | 朱素华. 芍药苷抑制糖尿病视网膜病变基质金属蛋白酶9激活的研究 [D]. 南京: 南京医科大学, 2017. |
| 31 |
Tao A, Song J, Lan T, et al. Cardiomyocyte–fibroblast interaction contributes to diabetic cardiomyopathy in mice: role of HMGB1/TLR4/IL-33 axis[J]. Biochim Biophys Acta Mol Basis Dis, 2015, 1852 (10): 2075- 2085.
doi: 10.1016/j.bbadis.2015.07.015 |
| 32 |
孟昭昀, 张燕群, 王秀玲, 等. 桂皮醛调控HMGB1/TLR4/NF-κB通路对糖尿病心肌病大鼠的心肌保护作用研究[J]. 中药材, 2024,, (4): 989- 992.
doi: 10.13863/j.issn1001-4454.2024.04.032 |
| 33 |
Zhu Z, Hu X. HMGB1 induced endothelial permeability promotes myocardial fibrosis in diabetic cardiomyopathy[J]. Int J Cardiol, 2017, 227, 875.
doi: 10.1016/j.ijcard.2015.11.024 |
| 34 |
Mudaliar H, Pollock C, Komala MG, et al. The role of Toll-like receptor proteins (TLR) 2 and 4 in mediating inflammation in proximal tubules[J]. Am J Physiol Renal Physiol, 2013, 305 (2): F143- F154.
doi: 10.1152/ajprenal.00398.2012 |
| 35 |
Huang L, Lin T, Shi M, et al. Liraglutide ameliorates inflammation and fibrosis by downregulating the TLR4/MyD88/NF-κB pathway in diabetic kidney disease[J]. Am J Physiol Regul Integr Comp Physiol, 2024, 327 (4): R410- R422.
doi: 10.1152/ajpregu.00083.2024 |
| 36 | 边咏馨. 牛磺酸对糖尿病肾病预防作用的研究 [D]. 沈阳: 沈阳农业大学, 2020. |
| 37 |
Zhou B, Li Q, Wang J, et al. Ellagic acid attenuates streptozocin induced diabetic nephropathy via the regulation of oxidative stress and inflammatory signaling[J]. Food Chem Toxicol, 2019, 123, 16- 27.
doi: 10.1016/j.fct.2018.10.036 |
| 38 |
熊刚, 邹华, 胡承莲, 等. 基于HMGB1/TLR4信号通路评价五味子乙素对2型糖尿病肾病大鼠肾脏功能的保护作用[J]. 医学研究杂志, 2019, 48 (3): 140- 143.
doi: 10.11969/j.issn.1673-548X.2019.03.032 |
| 39 |
Liu ZZ, Weng HB, Zhang LJ, et al. Bupleurum polysaccharides ameliorated renal injury in diabetic mice associated with suppression of HMGB1-TLR4 signaling[J]. Chin J Nat Med, 2019, 17 (9): 641- 649.
doi: 10.1016/s1875-5364(19)30078-0 |
| 40 |
何流, 金智生, 张磊, 等. 红芪多糖对糖尿病周围神经病变ob/ob小鼠高迁移率族蛋白1-Toll样受体4信号通路的影响[J]. 中国临床药理学杂志, 2019, 35 (7): 657- 660.
doi: 10.13699/j.cnki.1001-6821.2019.07.017 |
| 41 |
Zhang C, Hu J, Wang W, et al. HMGB1‐induced aberrant autophagy contributes to insulin resistance in granulosa cells in PCOS[J]. FASEB J, 2020, 34 (7): 9563- 9574.
doi: 10.1096/fj.202000605RR |
| 42 |
许月娇. 香青兰总黄酮对T2DM大鼠胰岛功能的影响及作用机制研究[J]. 湖北科技学院学报(医学版), 2021, 35 (6): 465- 468+474+456.
doi: 10.16751/j.cnki.2095-4646.2021.06.0465 |
| 43 |
Yan X, Xu P, Zhou L, et al. Blockade of high mobility group box 1 involved in the protective of curcumin on myocardial injury in diabetes in vivo and in vitro[J]. IUBMB life, 2020, 72 (5): 931- 941.
doi: 10.1002/iub.2226 |
| 44 |
Liu B, Li S, Sui X, et al. Root extract of Polygonum cuspidatum Siebold & Zucc. ameliorates DSS-induced ulcerative colitis by affecting NF-kappaB signaling pathway in a mouse model via synergistic effects of polydatin, resveratrol, and emodin[J]. Front Pharmacol, 2018, 9, 347.
doi: 10.3389/fphar.2018.00347 |
| 45 |
袁小波, 彭小珊, 周丽丽, 等. 荞麦黄酮通过下调HMGB1抑制高糖诱导的人视网膜微血管内皮细胞损伤的研究[J]. 中国免疫学杂志, 2023, 39 (11): 2311- 2317.
doi: 10.3969/j.issn.1000-484X.2023.11.013 |
| 46 |
尹延航, 陈绪才, 王益, 等. 芒果苷通过Nrf-2/HO-1/HMGB1/NF-κB通路减轻链脲佐菌素诱导的大鼠视网膜病变的机制探讨[J]. 中国社区医师, 2023, 39 (1): 12- 14.
doi: 10.3969/j.issn.1007-614x.2023.01.004 |
| 47 |
凌佼佼, 栾兰, 杨芳, 等. 葛花总黄酮对链脲佐菌素诱导糖尿病视网膜病变小鼠玻璃体血管内皮生长因子及高迁移率族蛋白B1信号通路的影响[J]. 中国医院用药评价与分析, 2020, 20 (7): 812- 816.
doi: 10.14009/j.issn.1672-2124.2020.07.012 |
| 48 | 韦艳, 李红, 苏晓庆, 等. 白藜芦醇对高糖环境下视网膜血管内皮细胞增殖及HMGB1乙酰化的影响[J]. 国际眼科杂志, 2015, 15 (12): 2049- 2051. |
| 49 |
Song J, Liu Q, Tang H, et al. Activation of PI3Kγ/Akt pathway increases cardiomyocyte HMGB1 expression in diabetic environment[J]. Oncotarget, 2016, 7 (49): 80803.
doi: 10.18632/oncotarget.13096 |
| 50 |
Chen J, Ye X, Yan T, et al. Adverse effects of bone marrow stromal cell treatment of stroke in diabetic rats[J]. Stroke, 2011, 42 (12): 3551- 3558.
doi: 10.1161/STROKEAHA.111.627174 |
| 51 |
Zhang H, Morgan B, Potter BJ, et al. Resveratrol improves left ventricular diastolic relaxation in type 2 diabetes by inhibiting oxidative/nitrative stress: in vivo demonstration with magnetic resonance imaging[J]. Am J Physiol Heart Circ Physiol, 2010, 299 (4): H985- H994.
doi: 10.1152/ajpheart.00489.2010 |
| 52 |
Wang WK, Lu QH, Zhang JN, et al. HMGB 1 mediates hyperglycaemia‐induced cardiomyocyte apoptosis via ERK/Ets‐1 signalling pathway[J]. J Cell Mol Med, 2014, 18 (11): 2311- 2320.
doi: 10.1111/jcmm.12399 |
| 53 |
刘思妤, 刘青, 彭群龙, 等. 二氢杨梅素通过抑制HMGB1改善糖尿病大鼠心功能不全[J]. 南方医科大学学报, 2022, 42 (5): 641- 648.
doi: 10.12122/j.issn.1673-4254.2022.05.03 |
| 54 |
Wu K, Zha H, Wu T, et al. Cytosolic Hmgb1 accumulation in mesangial cells aggravates diabetic kidney disease progression via NFκB signaling pathway[J]. Cell Mol Life Sci, 2024, 81 (1): 1- 15.
doi: 10.1007/s00018-024-05433-7 |
| 55 |
Jin J, Gong J, Zhao L, et al. Inhibition of high mobility group box 1 (HMGB1) attenuates podocyte apoptosis and epithelial‐mesenchymal transition by regulating autophagy flux[J]. J Diabetes, 2019, 11 (10): 826- 836.
doi: 10.1111/1753-0407.12914 |
| 56 | 马洪海. 黄芪甲苷纳米混悬剂的制备与评价及对糖尿病肾病的治疗 [D]. 哈尔滨: 哈尔滨商业大学, 2021. |
| 57 |
谢莹, 林鑫, 袁静, 等. 毛蕊花糖苷对糖尿病肾病小鼠肾组织中高迁移率族蛋白1及核因子κB表达的影响[J]. 中华肾脏病杂志, 2021, 37 (10): 817- 823.
doi: 10.3760/cma.j.cn441217-20201013-00121 |
| 58 |
Zhang FF, Morioka N, Harano S, et al. Perineural expression of high‐mobility group box‐1 contributes to long‐lasting mechanical hypersensitivity via matrix metalloprotease‐9 up‐regulation in mice with painful peripheral neuropathy[J]. J Neurochem, 2016, 136 (4): 837- 850.
doi: 10.1111/jnc.13434 |
| 59 |
Zhao X, Shen L, Xu L, et al. Inhibition of CaMKIV relieves streptozotocin-induced diabetic neuropathic pain through regulation of HMGB1[J]. BMC Anesthesiol, 2015, 16 (1): 1- 8.
doi: 10.1186/s12871-016-0191-4 |
| 60 |
Chen Q, Wang ZY, Chen LY, et al. Roles of high mobility group box 1 in cardiovascular calcification[J]. Cell Physiol Biochem, 2017, 42 (2): 427- 440.
doi: 10.1159/000477591 |
| [1] | Xiao XU, Shuailin WANG, Xin QIAN, Yi YAO, Zhangyu WANG, Xiaoyi ZHU, Qing MAO, Qi GUO. Research progress on the treatment of diabetic cardiomyopathy with traditional Chinese medicine [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2026, 31(6): 764-773. |
| [2] | Hao ZHANG, Haolin LI, Ping CHEN, Aihua WANG, Weigang CHENG, Qian BAI, Juanjuan YANG, Yuping YANG, Zhimin ZHANG, Haidong WANG. Effect of Yiqi Huoluo Formula on Th17/Treg balance in rheumatoid arthritis model rats via regulating the JAK2/STAT3 pathway [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2026, 31(5): 577-584. |
| [3] | Xiaoyan GAO, Juan GUO, Sheng HUANG, Qiaoyun WANG, Yujia HUANG, Jinyuan LI, Xiaoqiang LIU. Mechanism of Qinggan Ershiqiwei Wan on non-alcoholic steatohepatitis based on network pharmacology and in vivo experiments [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2026, 31(5): 596-606. |
| [4] | Mei CHENG, Zhaohui FANG, Jindong ZHAO, Fengxia SHENG, Mengnan MA. Liraglutide combined with metformin on glycolipid metabolism level and intima-media thickness in overweight/obese patients with type 2 diabetes mellitus [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2026, 31(5): 623-630. |
| [5] | Qun LI, Xinyue ZHANG, Shuo QI, Jin TAN. Research progress on the mechanism of TGF-β1/Smads signaling pathway in oral submucous fibrosis and regulation of traditional Chinese medicine [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2026, 31(5): 666-674. |
| [6] | Mina GAO, Liya YANG, Shangying DUAN, Xinlu CHEN, Xiaoya LI, Bo QIAO, Yueying WU. Research progress on the prevention and treatment of high-altitude diseases by traditional Chinese medicine based on the "lung-brain axis" [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2026, 31(5): 675-682. |
| [7] | Haodong YANG, Long LI, Jingxuan LUO, Jinglei LI. Research progress of Hippo pathway effector YAP/TAZ in idiopathic pulmonary fibrosis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2026, 31(5): 709-715. |
| [8] | Ying ZHOU, Juntong LIU, Qingfeng WANG, Yufeng YANG, Yan SHI. Research progress on pharmacological mechanism of traditional Chinese medicine targeting type 2 diabetes related pathways [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2026, 31(4): 500-508. |
| [9] | Jinju LI, Hao YANG, Nuobing RUAN, Qi XU, Zheng BI, Yufan LI, Fanjing WANG, Yixuan LIN, Zhaohui FANG. Research progress on cellular senescence and therapeutic drugs in diabetic microvascular complications [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2026, 31(4): 509-516. |
| [10] | Liya SUN, Jiaxin LI, Guiyan SUN, Zhichao CHEN, Qingfeng WANG, Yufeng YANG, Yan SHI. Research progress of traditional Chinese medicine in the prevention and treatment of diabetic nephropathy based on intestinal flora and branched-chain amino acids [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2026, 31(4): 527-535. |
| [11] | Shouyan HE, Minjun LIU, Cong WAN, Buzhen TAN. Research progress of PARP inhibitors therapy for endometrial cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2026, 31(4): 536-542. |
| [12] | Yajie BAI, Liuqing YANG, Qin FAN, Xuwei LIU, Yuchen HE, Jiamao CHENG, Haiyan CHEN. The anti-hepatic fibrosis mechanism of Dendrobium officinale poly saccharides in vitro through epithelial-mesenchymal transition and Notch signaling pathway [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2026, 31(3): 337-343. |
| [13] | Yuanyuan HUANG, Lingzhun WANG. Research progress in the intervention of myocardial fibrosis by regulating signal pathways with traditional Chinese medicine [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2026, 31(3): 372-381. |
| [14] | Furui WANG, Tian HUANG, Wenli JIANG, Zenan HU. Therapeutic advances in small-molecule drugs for moderate-to-severe ulcerative colitis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2026, 31(3): 392-399. |
| [15] | Pengfei WANG, Yuwei WANG, Fangmei JIN, Ping CHEN, Weiqing LI, Xuemei TIAN, Aihua WANG, Haidong WANG. The mechanism of action of Yiqi Huoluo formula in regulating the PI3K/Akt/mTOR pathway to suppress synovial inflammation in collagen-induced arthritis rats [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2026, 31(2): 213-222. |
| Viewed | ||||||
|
Full text |
|
|||||
|
Abstract |
|
|||||